{'fraction_non_alphanumeric': 0.03553921568627451, 'fraction_numerical': 0.015931372549019607, 'mean_word_length': 5.236641221374046, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Activity of 5-Flurouracil Metabolizing Enzyme Dihydropyrimidine Dehydrogenase(DPD) and its Association with Tumor Progression and Markers (CEA, CA19.9) in Patients with Colorectal Cancer

For the last seventy years, the fluoropyrimidine 5-fluorouracil (5-FU) has been placed as the first line chemotherapy in the treatment of various cancers including colorectal. DPD mediated conversion of 5-Flurouracil to dihydrofluorouracil (DHFU) is the rate-limiting step of 5-Flurouracil catabolism. The response rates of the 5-Flurouracil for advanced CRC is less.5-FU causes severe toxic effects with deficiency of DPD enzyme. The aim of this study was to Evaluate the kinetic and concentration of DPD in tissue with different stage of CRC, as well as Correlation between enzyme concentration and biomarker (CEA.CA19.9).